These efforts are helping Uganda make real progress towards being able to offer sustainable care to its community of people with bleeding disorders (PWBDs). Today we hear about how the federation—through WFH Humanitarian Aid Program donations and other support—has transformed the life of Adonia Musoke, a 34-year-old Ugandan with hemophilia A.
Adonia Musoke’s condition went undiagnosed for years. As a child, he suffered prolonged acute bleeds, gum bleeding and joint swelling. By age eight, mobility in his left arm was almost totally compromised, followed by his right at ten. Without a clear diagnosis, his future looked bleak. Then, in 2012, Musoke’s sister gave birth to a baby boy who exhibited similar symptoms. This led her to investigate the situation, and she soon discovered that her baby had hemophilia. Musoke then went to get himself tested—at which point he discovered that he too had the condition.
Newly diagnosed, Musoke started receiving factor infusion treatment which significantly improved his health. He also began receiving emotional and informational support from the Haemophilia Foundation of Uganda, the WFH national member organization (NMO) in the country. However, his journey took a negative turn in 2024: after a tooth extraction, he bled for a month despite factor VIII infusions. Doctors discovered he had developed inhibitors, preventing treatment from working. They then started giving him non-factor replacement therapy —donated by the WFH Humanitarian Aid Program. This therapy transformed Musoke’s life, alleviating his joint pain and essentially stopping his acute bleeds.
Today, Musoke earns a living as a shop attendant. He’s able to work consistently and hold a job because he doesn’t miss work due to bleeds. He credits his improved health to the WFH, and he is hopeful that more children with a bleeding disorder—like his nephew—will be diagnosed early, so that they can have a better quality of life than he did.
The WFH Humanitarian Aid Program has donated almost 20.3 million IUs of factor and over 224,000 mg of non-factor replacement therapy to Uganda since 2015. Over 2 million IUs of factor, and 57,000 mg of non-factor replacement therapy were donated last year alone. To find out more about the WFH Humanitarian Aid Program please click here.
About the WFH Humanitarian Aid Program
The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor. To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.
